The possibility that use of warfarin for atrial fibrillation among patients with chronic kidney disease could increase the risk of death or stroke has been suggested by some research.

About 52 percent of patients had moderate chronic kidney disease (CKD) or worse. The researchers found that warfarin treatment was associated with a lower l-year risk of a composite of the outcomes of death, heart attack, and ischemic stroke without a higher risk of bleeding. This association was observed in patients with moderate, severe, or end-stage CKD. The number of patients who developed the composite outcome, bleeding events, and the total of these 2 outcomes increased with the worsening of CKD categories, as did the rate at which these events occurred.
Editor's Note: This work was supported by a grant from the Swedish Foundation for Strategic Research. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, etc.
There will also be an audio author interview available for this study at 3 p.m. CT Tuesday, March 4, at jama.com.
Editorial: Warfarin Treatment in Patients With Atrial Fibrillation and Advanced Chronic Kidney Disease
Wolfgang C. Winkelmayer, M.D., M.P.H., Sc.D., and Mintu P. Turakhia, M.D., M.A.S., of the Stanford University School of Medicine, Palo Alto, Calif., (Dr. Winkelmayer is also an Associate Editor, JAMA), comment on the findings of this study in an accompanying editorial.
Advertisement
Editor's Note: Please see the article for additional information, including financial disclosures, funding and support, etc.
Advertisement
Source-Eurekalert